February 9, 2024 04:21 AM EST
Financing
Startups
Cell/Gene Tx

Pre­clin­i­cal biotech Metageno­mi prices $94M IPO at low end of pro­posed range

Kyle LaHucik

Senior Reporter

The bounc­er is let­ting a pre­clin­i­cal biotech en­ter the IPO club Thurs­day night.

Yes, the time­stamp is 2024. A pre­clin­i­cal Nas­daq of­fer­ing sounds like a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times